Serum LINC01127 serves as a diagnostic biomarker for sepsis and its predictive value for clinical outcomes.

BACKGROUND

This study aims to investigate the role of LINC01127 in sepsis and evaluate its potential clinical value.

METHODS

This study included 102 sepsis patients and 102 controls matched for age and gender. Serum levels of LINC01127 and miR-34b-5p were measured using quantitative real-time PCR (RT-qPCR). Receiver operating characteristic (ROC) curves were constructed to assess the diagnostic efficacy of LINC01127 for sepsis, while Kaplan-Meier curves evaluated its prognostic significance during 28-day follow-up. Lipopolysaccharide (LPS)-induced THP-1 cells were used to simulate an in vitro sepsis model. Enzyme-linked immunosorbent assay (ELISA) measured proinflammatory factor levels, and flow cytometry assessed apoptosis.

RESULTS

Serum LINC01127 exhibited downregulation in sepsis-affected individuals, while miR-34b-5p was upregulated. ROC curve analysis demonstrated that LINC01127 possesses good diagnostic value for sepsis. Kaplan-Meier analysis showed that low LINC01127 levels were associated with poorer prognosis during the 28-day follow-up. Bioinformatics analysis successfully predicted a binding site for miR-34b-5p on LINC01127, and dual-luciferase reporter (DLR) and RNA immunoprecipitation (RIP) assays confirmed their target relationship. Cell experiments demonstrated that upregulating LINC01127 significantly reduced the apoptosis and inflammation triggered by LPS, while increasing miR-34b-5p expression markedly reversed these effects.

CONCLUSION

LINC01127 may serve as a promising biomarker for sepsis, alleviating apoptosis and inflammatory responses through targeting miR-34b-5p. This offers novel insights into sepsis diagnosis and treatment.